Elsevier

Neuropharmacology

Volume 36, Issue 9, September 1997, Pages 1157-1165
Neuropharmacology

Review
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists

https://doi.org/10.1016/S0028-3908(97)00104-4Get rights and content

Abstract

The effects of putative A3 adenosine receptor antagonists of three diverse chemical classes (the flavonoid MRS 1067, the 6-phenyl-1,4-dihydropyridines MRS 1097 and MRS 1191, and the triazoloquinazoline MRS 1220) were characterized in receptor binding and functional assays. MRS1067, MRS 1191 and MRS 1220 were found to be competitive in saturation binding studies using the agonist radioligand [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)adenosine-5′-N-methyluronamide) at cloned human brain A3 receptors expressed in HEK-293 cells. Antagonism was demonstrated in functional assays consisting of agonist-induced inhibition of adenylate cyclase and the stimulation of binding of [35S]guanosine 5′-O-(3-thiotriphosphate) ([35S]GTP-γ-S) to the associated G-proteins. MRS 1220 and MRS 1191, with KB values of 1.7 and 92 nM, respectively, proved to be highly selective for human A3 receptor vs human A1 receptor-mediated effects on adenylate cyclase. In addition, MRS 1220 reversed the effect of A3 agonist-elicited inhibition of tumor necrosis factor-α formation in the human macrophage U-937 cell line, with an ic50 value of 0.3 μM.

References (40)

  • Y. Yao et al.

    Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3, antagonists

    Biochemistry and Biophysics Research Communication

    (1997)
  • H. Ali et al.

    Sustained activation of phospholipase-D via adenosine A3 receptors is associated with enhancement of antigen-ionophore-induced and Ca2+-ionophore-induced secretion in a rat mast-cell line

    Journal of Pharmacological Experimental Therapy

    (1996)
  • O. Alunlakshana et al.

    British Journal of Pharmacology and Chemotherapy

    (1959)
  • S. Ceruti et al.

    Dual actions of adenosine A3 receptor agonists on mammalian astrocytes: protection at low concentrations and apoptosis at high concentrations

    Drug Development Research

    (1996)
  • W. Daubener et al.

    Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-gamma and tumor necrosis factor-alpha

    European Journal of Immunology

    (1996)
  • T.V. Dunwiddie et al.

    Activation of hippocampal adenosine A3 receptors produces a heterologous desensitization of A1 receptor mediated responses in rat hippocampus

    Journal of Neuroscience

    (1997)
  • R. Haas et al.

    TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens

    European Journal of Cellular Biology

    (1989)
  • K.A. Jacobson et al.

    A3 adenosine receptors: design of selective ligands and therapeutic prospects

    Drugs of the Future

    (1995)
  • M.A. Jacobson et al.

    Novel selective non-xanthine selective A3 adenosine receptor antagonists

    Drug Development Research

    (1996)
  • X.-D. Ji et al.

    Interactions of flavonoids and other phytochemicals with adenosine receptors

    Journal of Medical Chemistry

    (1996)
  • Cited by (135)

    • P2Y<inf>13</inf> receptors mediate presynaptic inhibition of acetylcholine release induced by adenine nucleotides at the mouse neuromuscular junction

      2016, Neuroscience
      Citation Excerpt :

      On the other hand, IDP might be metabolized into inosine, which we demonstrated is able to activate A3 adenosine receptors and decrease spontaneous and evoked ACh release at mammalian MNJs (Cinalli et al., 2013). So, to rule out the possibility that IDP may exert its inhibitory effect through its metabolite inosine, we studied its action in the presence of the specific A3 receptor antagonist MRS-1191 (5 μM; Jiang et al., 1996; Jacobson et al., 1997). In these conditions, the effect of 100 μM IDP upon MEPP frequency remained unchanged (MRS-1191 99.5 ± 0.7% of control values, MRS-1191 + IDP 59.1 ± 1.5%, n = 3, P < 0.001, Fig. 3C), suggesting that IDP modulates spontaneous secretion by activating P2Y13 receptors.

    • ATP releases ATP or other nucleotides from human peripheral blood leukocytes through purinergic P2 receptors

      2016, Life Sciences
      Citation Excerpt :

      We chose this relatively low concentration of ATPγS because at higher concentrations, it causes cell death [35]. Finally, in another set of experiments, a mixture of MNC + PMN cells were pre-incubated with or without 100 nM 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, an antagonist of A1 receptors [36]), 10 μM MRS 1191 (an antagonist of A3 receptors [37]), 100 nM SCH-58261 (SCH, an antagonist of A2A receptors [38]), or 10 μM MRS 1754 (an antagonist of A2B receptors [39]). All the antagonist or inhibitor drugs were pre-incubated during 10 min before ATP, UTP, or ATPγS addition.

    View all citing articles on Scopus
    View full text